Brief: Mustang Bio Announces Updated Interim Phase 1/2 Data For MB-106 CD20-Targeted CAR T in Patients with Chronic Lymphocytic Leukemia
11/06/2021 11:39
June 11 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO ANNOUNCES UPDATED INTERIM PHASE 1/2 DATA FOR
MB-106
CD20-TARGETED CAR T IN PATIENTS WITH RELAPSED OR REFRACTORY
B-CELL NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA
* MUSTANG BIO INC - 93% OVERALL RESPONSE RATE AND 67%
COMPLETE
RESPONSE RATE IN PATIENTS TREATED WITH MODIFIED CELL
MANUFACTURING PROCESS
Source text for Eikon: ID:nGNX4gF61b
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie